French biotech armed with Series A looks to build out manufacturing facility for plant-based protein tech
Using plant-based supply to manufacture vaccines and other pharmaceutical materials has become more prevalent in the biotech space, but one French biotech is looking to apply it to the cell therapy market.
Core Biogenesis, based in Strasbourg, France, uses a plant-based bioproduction platform to produce proteins. According to CEO Alexandre Reeber, the company uses camelina, otherwise known as wild flax traditionally used in gastronomy, to manufacture proteins from the seeds of the plant. Core has secured $10.5 million in a Series A to push its tech forward.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
